Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
NOP17 CRISPR/Cas9 KO Plasmid (h): sc-407256
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- NOP17 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the NOP17 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: NOP17 Antibody (A-10): sc-514127
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
NOP17 CRISPR/Cas9 KO Plasmid (h) | sc-407256 | 20 µg | $397.00 |
Overview
PIH1D1 encodes NOP17, a conserved cochaperone within the R2TP complex that partners with HSP90 to promote the biogenesis, stabilization, and assembly of large macromolecular machines. NOP17 supports maturation of box C/D snoRNPs, contributes to ribosome biogenesis and nucleolar homeostasis, and helps assemble key complexes such as RNA polymerase II and PIKK-containing signaling modules. Through these functions, PIH1D1 links chaperone-mediated quality control to RNA processing, proteostasis, and stress-responsive pathways. Dysregulation of R2TP/HSP90-dependent assembly and ribonucleoprotein biogenesis has been associated with altered growth control and genome maintenance phenotypes relevant to mechanistic disease research.
NOP17 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the PIH1D1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the PIH1D1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the PIH1D1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish NOP17 protein expression.
This CRISPR knockout system enables efficient generation of PIH1D1-deficient cell models for investigation of NOP17 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting PIH1D1 exon(s) critical for NOP17 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple PIH1D1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by NOP17 CRISPR/Cas9 KO Plasmid (h) and NOP17 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the PIH1D1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by NOP17 HDR Plasmid (h) and NOP17 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by PIH1D1 homology arms to support homology-directed repair at defined PIH1D1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.